Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

Summit Therapeutics has agreed to sell its investigational Phase III antibiotic ridinilazole to Biossil, Inc., an AI-driven biopharma company dedicated to tackling life-threatening conditions with significant unmet medical needs. This move could allow Biossil to advance ridinilazole further through its AI-enhanced processes, potentially bringing a new treatment option to market sooner. The transaction highlights the growing trend of biotech firms leveraging AI to expedite drug development and highlights the importance of precision antibiotics in combating resistant infections.